Search results for: Multi-Indication Medicines
Filter search results
Three seminars forthcoming at OHE
12 May 2016
…terms of outcomes achieved / unit cost, and (b) multi-year population based outcome based commissioning. These attempts represent fundamental change, and practical implementation, Nick will describe how this has not…
New Publication: EuroQol Protocols for Time Trade-Off Valuation of Health States
8 June 2016
…TTO variants leads to two practical problems: incomparability across studies and difficulty in choosing among the variants. The EuroQol Group, an international, multi-disciplinary network of researchers, has developed three standardised…
OHE Workshop: Surrogate Endpoints as Predictors of Overall Survival in Oncology
14 July 2016
…of PFS as a surrogate. Additionally, there was a consensus on the fact that the validity of the surrogates is affected by multiple factors such as cancer type, drug mechanism…
OHE Awarded Funding for Seven Projects by the EuroQol Research Foundation
18 July 2016
…re-analyse the qualitative and quantitative data which were generated from a representative sample of the general public, using alternative analytic methods such as non-metric multidimensional scaling and Q-sort. Results will…
OHE is Pleased to Host Four MSc Students for 2016
26 July 2016
…preferences relating to adults. The aim of this project is to evaluate data that have been collected as part of a multi-country study (UK, Spain, Germany and the Netherlands) to…
The Application of Anchoring Vignettes to the EQ-5D-5L: A Possible Solution to Reporting Heterogeneity in PROMs
30 August 2016
…have on multi-national trials. Slides of a recent presentation of this programme of work given at the London Health Economics Group are available here. Additional references: Knott, R., Au, N.,…
New OHE Research Paper: Extrapolation from Progression Free Survival to Overall Survival in Oncology
28 December 2016
…shows that the validity of surrogates is affected by multiple factors such as cancer type, drug mechanism of action, phase of development, year of the trial, subsequent treatments and stage of…
Comparing the Cancer-Specific EORTC-8D and the Generic EQ-5D-3L
4 January 2017
…condition-specific QALYs were found to be similarly sensitive to a number of patient and disease characteristics. When specifically considering the difference in QALYs (condition-specific minus generic QALY estimates) multivariate regression…
OHE Lunchtime Seminar with Andrea Manca: Economic Evaluation for Decision-making and the Value of Access to Individual Patient Data
16 January 2017
…health technologies under scrutiny. The evidence base available to the HTA agency is often multifaceted and fragmented, comprising a mix of aggregate (or summary level data – AD) and individual patient-level…